THERAtRAME — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

THERAtRAME is an early-stage biotech pioneering a novel approach in oncology by targeting transfer RNA (tRNA) epitranscriptomics with small molecules. The company, spun out from academic research, is developing a platform to discover drugs that interfere with the RNA modification machinery, a process implicated in cancer progression and drug resistance. As a private, preclinical-stage company, it is likely reliant on grant funding and venture capital to advance its research. Its success hinges on validating this emerging biological pathway and translating its discoveries into viable drug candidates.

Oncology

Technology Platform

Platform for discovering small molecules that target tRNA epitranscriptomic modifications (e.g., methylation) to disrupt cancer-specific protein translation.

Opportunities

Pioneering a novel drug class in the large and growing oncology market.

First-in-class status offers potential for strong IP and premium pricing.

Growing scientific validation of RNA modifications in disease creates a receptive environment for this approach.

Risk Factors

High scientific risk associated with targeting a novel and complex biological pathway.

Early-stage, pre-revenue status with dependence on external funding.

Long development timelines and high attrition rates typical of drug discovery.

Competitive Landscape

The field of tRNA epitranscriptomics is emerging, with a small number of academic groups and early-stage biotechs (e.g., Gotham Therapeutics, Storm Therapeutics, Accent Therapeutics) exploring RNA modification targets broadly. Competition is currently limited but expected to intensify as the biology is further elucidated. THERAtRAME's specific focus on tRNA (vs. mRNA) may provide a differentiated niche.

More companies in Small Molecule Drugs →More companies in Belgium →